ACC Welcomes New CEO!

It is my pleasure to announce that Shalom “Shal” Jacobovitz has been selected as the ACC’s new chief executive officer (CEO).  Shal was chosen as CEO following a year-long nationwide search led by executive search firm, Korn/Ferry International. He will assume his new role in the coming weeks. Shal comes to the ACC from Actelion Pharmaceuticals, U.S., a biopharmaceutical company specializing in cardio-pulmonary therapies, where he has served as president since 2004. Prior to Actelion, he held positions at F. Hoffmann La Roche, including serving as general manager for Central America and the Caribbean where he was responsible for the Pharmaceutical, OTC and Diagnostic division activities. He also served as the global lifecycle leader for cardiovascular products based in Basel, Switzerland. He has also held positions with Abbott Canada, Nordic Labs and Marion Merrill Dow (now known as Aventis) in Canada. Shal earned his Bachelor of Science degree in biology at the University of Western Ontario in Canada. This is an exciting time for the College and we are excited about the skills and talents that Shal brings to the CEO position. With more than 25 years in the health care environment, he is a great choice to lead this strong organization and take it to the next level in this period of change in the health care environment. He is an innovative and proven leader, as well as a successful mentor. His clear commitment to quality, innovation and strategic ma...
Source: ACC in Touch Blog - Category: Cardiology Authors: Tags: Professionalism Source Type: blogs